Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Considerations for drug development in hematological oncology

Matti Aapro • 12 Jun 2015
EHA 2015
General

At the 20th Congress of the European Hematology Association (EHA), Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, highlights the progress of novel therapeutic agents and approaches in the field of hematological oncology and the need to find a balance between health care affordability and profits that will allow this continued innovation.

More from Matti Aapro

2:33
Improving outcomes in elderly patients with cancer
Matti Aapro • 12 Jun 2015

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals